• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
 
  • Details
  • Full
Options
2015
Journal Article
Title

Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)

Abstract
Background: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. Methods: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). Results: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. Conclusions: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs.
Author(s)
Zscharnack, Matthias
Universität Leipzig
Krause, Christoph
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Aust, Gabriela
Universität Leipzig
Thümmler, Christian
Universität Leipzig
Peinemann, Frank
Universität Leipzig
Keller, Thomas
ACOMED Statistik Leipzig
Smink, Jeske J.
co.don AG, Teltow
Holland, Heidrun
Universität Leipzig
Somerson, Jeremy S.
University of Texas, San Antonio
Knauer, Jens  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Schulz, Ronny Maik
Universität Leipzig
Lehmann, Jörg  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Journal
Journal of translational medicine  
Open Access
DOI
10.1186/s12967-015-0517-x
Additional link
Full text
Language
English
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Keyword(s)
  • ATMP

  • biodistribution

  • cartilage repair

  • chondrocytes

  • safety

  • tumorigenicity

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024